ArticleBMC cancer2025
Clinical outcomes by bone metastasis uptake pattern in differentiated thyroid cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protein expression of glucose metabolism and somatostatin receptor between primary tumor and distant metastasis in differentiated thyroid cancer.Annals of nuclear medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundsPatients with differentiated thyroid cancer (DTC) and bone metastases (BM) exhibit heterogeneous radioactive iodine (RAI) and fluorine-18-fluorodeoxyglucose (
methodsPatients confirmed DTC with BM were involved in this study between 2006 and 2021. All patients received
resultsAmong 67 enrolled DTC patients with BM, three uptake patterns were identified: RAI+/PET- (18 patients, 26.9%), RAI+/PET+ (40 patients, 59.7%), and RAI-/PET+ (9 patients, 13.4%). Univariate analysis revealed that age stratification, serum thyroglobulin (Tg) levels, and BM uptake pattern significantly impacted progression-free survival (PFS) and overall survival (OS). Critically, RAI+/PET + patients with RAI(+) ratio > 50% showed better PFS (range 12-156 months, median 38.5 months, p = 0.000) and OS (range 20-156 months, median 61.5 months, and p = 0.012) than those with RAI(+) ratio [Formula: see text]50% (PFS: range 6-92months, median 24 months; OS: range 28-112 months, median 51 months). Multivariate analysis identified total total lesion glycolysis of all bone lesions (tTLG) from PET/CT as an independent prognostic factor for both PFS and OS (p = 0.021 and p = 0.035, respectively).
conclusionsThe RAI(+) ratio determines clinical outcomes, and the prognosis of RAI+/PET + patients resembles that of RAI+/PET- patients, suggesting similar biological behavior in DTC patients with BM. Pretreatment tTLG is a significant independent prognostic marker for PFS and OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.